A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer therapeutics, is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial ...

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about ...

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

UK pharma major GSK on Friday announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Blenrep (belantamab mafodotin) in combinations with bortezomib plus ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Leading cybersecurity company Surfshark is celebrating its 7th anniversary. For that occasion, it offers users a limited-time birthday deal. As part of its birthday celebration, Surfshark is offering ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...